Une belle compagnie de Québec qui fait dans les plantes est Medicago.
1 « J'aime »
Providing Precisely What the Pharma World Needs – Initiating
Coverage on ImmunoPrecise Antibodies with a Buy Rating and
$2.10 Target .
Bon timing 
IA initiating BUY IPA.pdf (1,3 Mo)
2 « J'aime »
Il a fait ses calculs avec 69M de S/O 
Est-ce que je me trompe ou quelqu’un a déjà mentionné sur le forum que l’entreprise vise un listing sur le Nasdaq dans les prochains mois? … information qui ne figure pas sur le rapport.
On connait tous l’impact d’un listing US sur le prix, donc la cible de 2.10$ ne tiendrai pas compte de ce facteur?
Oui la compagnie va annoncer sous peu
1 « J'aime »
C’est pas vraiment quantifiable un uplisting.
C’est certain que ca peut faire un “pop” au début mais a plus long-terme, l’exécution et les résultats font foi de tout (voir XBC).
Le listing NASDAQ est dans les plans depuis au moins Janvier 2018. Cette fois-ci ca semble être la bonne 
1 « J'aime »
Je ne suis pas vraiment d’accord non plus avec les comparables qui ont été choisis. En fait, c’était surement difficile de trouver des bons comparables et je peux comprendre que certains ne soient pas tout à fait similaires.
Par contre, là où j’ai un (gros) problème, c’est que l’analyste utilise un multiple des revenus alors que 3 des 4 comparables n’ont pas de revenus. Elle fait donc une moyenne des 4, mais essentiellement ça revient à prendre Bionano (la seule qui a des revenus) et à diluer ses ratios avec d’autres compagnies bidons pour que le multiple des revenus paraisse plus élevé.
Je viens de lui écrire pour lui faire part de mon désaccord avec sa manière de procéder.
PS: @simba007 tu t’es trompé de compagnie, ce n’est pas Envio 360 mais plutôt EVIO Labs.
Effectivement, je suis d’accord avec toi. Peut-être qu’un listing sur le NASDAQ peut aider l’entreprise à obtenir une meilleure valorisation dans le marché, mais ça ne change pas la valeur intrinsèque de l’entreprise.
1 « J'aime »
ImmunoPrecise Reports Record Revenues and Positive Adjusted EBITDA Fiscal 2020
NEWS PROVIDED BY
Aug 31, 2020, 07:30 ET
Reports rapid advancement of COVID-19 antibody programs;
combination studies achieve nearly complete neutralization of SARS-CoV-2
VICTORIA, BC, Aug. 31, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the « Company » or « IPA ») (TSXV: IPA) (OTCQB: IPATF) today announced financial results and provided a business update for its fiscal year 2020.
Recent Highlights:
- Characterized a subset of fully human, therapeutic antibodies shown to have potent neutralizing activity and exhibiting enhanced neutralization upon combinatorial (dual antibody) testing
- Awarded multiple grants for the development of antibody therapeutics against SARS-CoV-2
- Announced TRANSVAC2 funding collaborative COVID-19 vaccine project between ImmunoPrecise Antibodies Europe and LiteVax BV
- IPA subsidiary, UPE, joining Genmab and Merus in expansion to new biotech accelerator in the Center of European Science Industry
- Collaborating with the NIH and Integrated Biotherapeutics to study the structural details of antibodies with therapeutic potential to treat or prevent COVID-19
- Awarded grant by SERC to fund collaboration with the University of Victoria to develop a potential saliva-based COVID-19 antibody test designed to provide real-time results
- Added to WHO draft landscape of companies combating COVID-19
- Integrated SGI’s automated DNA Printer at Utrecht Site, first in Europe
Financial Results
Revenue. The Company posted record revenue of $14,057,927 compared to revenues of $10,926,268 in the 2019 fiscal year, a 29% increase in revenue for the year. Revenue in Q4 was up 57% over Q4 2019. The Company’s continued focus on identifying and onboarding new clients seeking the breadth and depth of the end-to-end services offered, combined with continued growth to core existing client business, led to increases in both volume and financial value of contracts during the year ended April 30, 2020. Revenue outlook is positive for the first quarter of fiscal 2021.
Gross Margin. Gross profit increased 52% to 8,033,984, compared to 5,294,634 for the for the same period last year an increase of $2,739,350 over year-end April 30, 2019.
Net Loss. The Company reported a net loss of $4,947,426 for year ended April 30, 2020compared to a net loss of $7,617,467 for the same periods last year, a $2,670.041improvement over prior year. The decrease in net loss is primarily attributable to the increase in gross profit.
Non-IFRS Measures* Adjusted EBITDA for the year was $52,311 compared to ($2,849,474) for fiscal year ending April 30, 2019. This significant improvement in Adjusted EBITDA is primarily a result of the increase in gross profit compared to the prior year.
« It was a record fiscal year for ImmunoPrecise, a result of our ongoing partnerships with pharma and biotech companies from across the globe, coupled with the continued addition of new clients for research, diagnostic and therapeutic programs, » said Jennifer Bath, chief executive officer of ImmunoPrecise. « We work diligently alongside our clients to help them build pipelines and research programs, serving as an innovative extension of their laboratories and building lasting relationships. We are rapidly gaining traction in the market, and I am pleased to report our customer base has grown to include over 400 of the leading pharma and biotech companies worldwide, as well as more than half of the top twenty global pharma companies. We anticipate the continuance of this trend in larger, multi-year agreements to be further bolstered by a robust out-licensing strategy. »
« In addition to our strong financial performance, I am pleased to report rapid development of our COVID-19 program. As we have shared previously, current vaccine strategies under development for SARS-CoV-2 are designed to protect uninfected individuals. However, these approaches do not address patients with active disease and will likely not be effective in a number of critical populations including the elderly and immunocompromised. Moreover, given the high potential for continued virus mutation, alternative treatments targeting limited epitopes may not provide long-term efficacy. In contrast, our antibody discovery platforms represent a powerful treatment option for COVID-19 patients generating unparalleled diversity of novel human antibodies, which is being designed to provide maximum clinical benefit for both current and future variants of the virus. »
« I am pleased to report that our lead antibodies have produced clear synergistic effects, confirming their activities are enhanced in combination studies and resulting in near complete neutralization of SARS-CoV-2 pseudovirus infection. We are now accelerating pre-clinical testing with plans to submit an IND to the FDA as soon as practical. In the meantime, we are actively pursuing additional collaboration and partnership opportunities. We have also been awarded multiple grants, which further validate our platform, and we will continue to actively explore other non-dilutive funding opportunities. »
« Lastly, we are excited to partner with Dr. Alexandre Brolo’s lab at the University of Victoria (« UVic »), to develop a saliva-based antibody-based test for the detection and screening of COVID-19. Unlike current immunoassays that are developed for blood or serum, our goal is to develop a test kit that will provide rapid results, and can be easily administered anywhere, including at home. Overall, we are highly encouraged by the progress of our programs, all leveraging our core antibody expertise, and we look forward to providing further updates. »
4 « J'aime »
ImmunoPrecise to Present at The LD 500 Virtual Investor Conference
Monday, August 31, 2020 10:30 AM
Share this article now
Topic:
Conferences
VICTORIA, BC / ACCESSWIRE / August 31, 2020 / IMMUNOPRECISE ANTIBODIES LTD. (the « Company » or « IPA ») (TSXV:IPA)(OTCQB:IPATF)(FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced today announced that CEO Jennifer Bath will present to investors attending the LD 500 investor conference on Friday, September 4, 2020 at 1:00pm EST. Dr. Bath will also host one-on-one investor meetings on September 2 and September 4.
« ImmunoPrecise has emerged as a leader in a US$40B therapeutic discovery market. Between our COVID-19 research, rapidly expanding pipeline, and our continuously growing pipeline of programs, we have many fantastic updates to share. We look forward to discussing these developments and more with investors attending the LD 500 conference. »
View Dr. Bath’s video presentation
here: https://www.webcaster4.com/Webcast/Page/2019/36980
To book a meeting, register here: https://ld-micro-conference.events.issuerdirect.com/.
« We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space, » said Chris Lahiji, Founder of LD.
The LD 500 will take place on September 1st through the 4th.
View ImmunoPrecise’s profile here: https://www.ldmicro.com/profile/IPA.V.
Profiles powered by LD Micro - News Compliments of Accesswire
About LD Micro
Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.
What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.
The upcoming « 500 » in September is the Company’s most ambitious project yet, and the first event that is accessible to everyone.
For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com.
For further information: For investor relations please contact: Frederick Chabot, Phone: 1-438-863-7071, Email: frederick@contactfinancial.com, Contact Financial Corp., Suite 810, 609 Granville Street, P.O. Box 10322, Vancouver, B.C., V7Y 1G5, Canada.
1 « J'aime »
2 « J'aime »
Paul semble très excité et confiant! BUY
Je peux pas croire qu’elle utilise encore 69M de S/O, pas fort.
C’est sur que c’est moins flashy utiliser les FDSO pour mettre un PT sous le SP actuel
Au moins elle a changé les comparables! Je lui avais écrit pour lui dire que je n’étais pas d’accord avec ses comparables et je lui en avais suggéré quelques-un qu’elle a incorporé dans sa mise à jour d’aujourd’hui. C’est bien de voir qu’elle s’adapte. Je pense qu’elle a surtout une expertise en santé et moins en modélisation financière.
Je suis d’accord avec ton commentaire @djudes concernant les actions pleinement diluées et je lui ai envoyé le commentaire.
1 « J'aime »
Elle utilise Q4 il y a pas de fautes. Je comprend pas ton commentaire
Elle utilise 69.2M qui était son estimation initiale de ce que serait le nombre d’actions à la fin du Q4. Le Q4 a été publié et il ya 69.9M d’actions en circulation au 30 avril. Le rapport de gestion mentionne également que c’est rendu à 74.1M au 28 août avec l’exercice des options et warrants.
Comme 100% des options, warrants et débentures convertibles sont ‹ ‹ in the money › › présentement, elle devrait utiliser le nombre d’actions pleinement diluées (96,7M) pour mieux refléter la réalité. Cependant, ça ferait baisser le prix cible. Elle m’a dit qu’elle avait eu ce commentaire de d’autres investisseurs aussi et qu’elle allait faire l’ajustement lorsqu’elle aura une opportunité dans une prochaine mise à jour.
1 « J'aime »
Si les W ne sont pas exercés tu ne peux pas les inclure. C’est noté pour le 69.2
1 « J'aime »
